BIOR vs. XGN, RNLX, DMTK, ENZ, CUE, SCYX, HILS, BYSI, DERM, and RLMD
Should you be buying Biora Therapeutics stock or one of its competitors? The main competitors of Biora Therapeutics include Exagen (XGN), Renalytix (RNLX), DermTech (DMTK), Enzo Biochem (ENZ), Cue Biopharma (CUE), SCYNEXIS (SCYX), Hillstream BioPharma (HILS), BeyondSpring (BYSI), Journey Medical (DERM), and Relmada Therapeutics (RLMD).
Exagen (NASDAQ:XGN) and Biora Therapeutics (NASDAQ:BIOR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, community ranking, profitability, earnings, analyst recommendations, valuation and risk.
Exagen received 15 more outperform votes than Biora Therapeutics when rated by MarketBeat users. However, 71.43% of users gave Biora Therapeutics an outperform vote while only 54.05% of users gave Exagen an outperform vote.
75.3% of Exagen shares are held by institutional investors. Comparatively, 43.7% of Biora Therapeutics shares are held by institutional investors. 26.1% of Exagen shares are held by company insiders. Comparatively, 51.0% of Biora Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Exagen presently has a consensus target price of $7.00, indicating a potential upside of 251.76%. Biora Therapeutics has a consensus target price of $15.00, indicating a potential upside of 1,937.21%. Given Exagen's higher possible upside, analysts clearly believe Biora Therapeutics is more favorable than Exagen.
Exagen has higher revenue and earnings than Biora Therapeutics. Exagen is trading at a lower price-to-earnings ratio than Biora Therapeutics, indicating that it is currently the more affordable of the two stocks.
Biora Therapeutics has a net margin of 0.00% compared to Biora Therapeutics' net margin of -34.74%. Exagen's return on equity of 0.00% beat Biora Therapeutics' return on equity.
Exagen has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, Biora Therapeutics has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500.
In the previous week, Biora Therapeutics' average media sentiment score of 0.00 equaled Exagen'saverage media sentiment score.
Summary
Exagen beats Biora Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Biora Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIOR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BIOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biora Therapeutics Competitors List
Related Companies and Tools
